ABSTRACT-Pulmonary Fas activation is essential in the pathogenesis of the acute respiratory distress syndrome. It remains unclear whether Fas-induced lung injury is dependent on neutrophils or mainly triggered by epithelial cell apoptosis. The contribution of lung epithelial cells (LEC) and alveolar macrophages (AM) remains elusive. Mice were neutrophil reduced prior to intratracheal instillation of Fas-activating (Jo2) or isotype antibody for 6 or 18 h. LEC and AM were incubated with Jo2 and in the presence of nuclear factor kappa B, p-38 mitogen activated protein kinase (p38MAPK), or extracellular signal regulating kinase 1/2 (ERK1/2) inhibitors. Cytokines were assessed by cytometric bead array or ELISA. Apoptosis was quantified via active caspase-3 Western blotting and Terminal Deoxynucleotide Transferase dUTP Nick End Labeling (TUNEL). Lung injury was assessed by bronchoalveolar lavage fluid (BALF) protein concentration and lung histology. KC, IL-6, and MCP-1 were markedly increased in lung, plasma, and BALF 18 h after Jo2 in the presence of neutrophils; in neutrophil-reduced mice lungs, MCP-1, but not KC or IL-6, was even further enhanced. Six hours after Jo2, BALF protein was markedly increased only in the presence of neutrophils. Apoptosis remained unaffected by neutrophil reduction. AM released MCP-1 and underwent apoptosis at lower concentrations of Jo2 than LEC. Inhibition of p38MAPK significantly increased, while inhibition of ERK1/2 reduced AM and LEC apoptosis. In conclusion, neutrophils are a necessary component of Fas-induced lung damage, while not affecting lung apoptosis directly per se. LEC display higher resistance to Fas-triggered inflammation and apoptosis than AM.
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) present a worldwide medical challenge (1, 2) associated with high morbidity and mortality (3) . ALI/ARDS arises from hetero-pathogenetic processes, which collectively culminate in pulmonary neutrophil influx and activation, lung inflammation, disruption of the alveolar-capillary barrier, intra-alveolar edema, and atelectasis (2) . The pathomechanistic role of neutrophils (PMN) seems to strongly depend on the underlying pathophysiology. In this regard, hyperoxia-, or oleic acid-induced ALI has been found to be independent of the presence of neutrophils (4), whereas previous PMN reduction was protective in chest trauma-induced septic acute lung injury (5) .
Pulmonary Fas activation is a key mechanism in the pathogenesis of ALI/ARDS. The deficiency of Fas or FasL and the inhibition of downstream effectors like caspase-3 showed the capacity to reduce ALI in experimental settings (6) (7) (8) . In this regard, Fas-induced lung epithelial cell (LEC) apoptosis appears to be involved in the breakdown of the alveolarcapillary barrier. Human LECs express Fas and are responsive to FasL-induced apoptosis especially in the distal airways (9) . Cellular FLICE inhibitory protein (c-FLIP) has been shown to play an important role in non-apoptotic Fas-signalling, with its long splice variant c-FLIP L acting as an adapter-like molecule within the death-inducing signalling complex, switching from apoptotic to inflammatory signalling via nuclear factor kappa B (NF-kB) (10) , extracellular signal regulating kinase 1/2 (ERK1/ 2), and p-38 mitogen activated protein kinase (p38MAPK) (11) , thus promoting PMN recruitment into the lungs. Therefore, activation of Fas potentially links pulmonary cytokine release, PMN recruitment, and LEC apoptosis in leading to the disruption of the alveolar-capillary barrier (12) .
So far it remains unclear whether Fas-induced lung injury is dependent on the consecutive immigration of activated PMNs into the lungs (neutrophil hypothesis), or is mainly triggered by apoptosis of LEC directly per se (epithelial cell hypothesis) (13) . In addition, the response of alveolar macrophages (AM) and LEC to Fas remains elusive. Therefore, our aim was to investigate the contribution of PMN to Fas-induced lung damage and apoptosis in vivo, as well as the effect of Fas on AM and LEC apoptosis and inflammation in vitro. Here, we have found that PMNs are a necessary premise of Fas-induced lung injury in vivo. Inflammation but not apoptosis was tightly regulated by the presence of neutrophils. In vitro, LECs appeared to be more resistant than AM to Fas-induced apoptosis and rather produced PMN attracting chemokines.
MATERIALS AND METHODS

Animals
Male C57Bl/6 mice (Charles River, Sulzfeld, Germany), 13-week old, were used in all the studies described here. Experiments were approved by the
BAL neutrophil count
Ten microliters of BALF were mixed with 1 mL of crystal violet, the stained cells were then differentiated and counted by light microscopy in a Neubauer chamber as described before for total leukocyte quantification (5). BALF samples were centrifuged, the cell pellet diluted in a volume of PBS equivalent to the amount of received BAL fluid, the cell suspension was subsequently cytospun (Zytozentrifuge; Shandon, Franfurt, Germany), fixed in 100% methanol (Fluka, Deisenhofen, Germany) and stained with a modified Pappenheim stain (Merck, Darmstadt, Germany). PMN quantification was achieved by surveying 200 leukocytes via light microscopy at Â100 magnification independently by two experienced and blinded members of our research group.
Lung tissue homogenization
Tissue homogenization for cytokine measurements and Western blotting was performed as described previously (5) .
Protein concentration
Protein concentration was measured using a BCA Protein Assay Kit (Pierce, Rockford, Ill), as described previously (8) .
Flow cytometry
Whole blood leukocytes (CD45 positive) and neutrophils (CD45 positive/ CD3e negative) were quantified by staining with a CD3e and CD45-PE monoclonal antibody (Immunotech, Krefeld, Germany) in addition to characteristic side and forward scatter profiling via fluorescence activated cell sorting analysis.
Quantification of cytokines/chemokines and myeloperoxidase activity MCP-1, MIP-2, and KC were quantified in plasma, BALF, and lung tissue homogenate as described before (14) . IL-1b, IL-6, IL-10, macrophage inflammatory protein-1a (MIP-1a), and granulocyte-colony stimulating factor (G-CSF) were measured using the cytometric bead array technique (BD Biosciences, San Diego, Calif) as described elsewhere (8) . Myeloperoxidase activity was measured as previously described (17) .
Active caspase-3 and b-actin western blotting
Lung tissue active caspase-3 and b-actin were analyzed via Western blotting as described previously (5) and quantified using ImageJ (NIH) (18) .
TUNEL and hematoxylin-eosin staining
The left lungs were paraffin embedded and 1-mm sections were cut from identical location for staining. Terminal Deoxynucleotide Transferase dUTP Nick End Labeling (TUNEL) and hematoxylin-eosin (H&E) staining were conducted as described before (15) . H&E-stained slides were independently evaluated via light microscopy at Â400 magnification by two instructed members of our research group looking for evidence of distension of alveoli, thickening of alveolar septa, perivascular and peribronchial edema, and intraalveolar cellular infiltrates as described previously (5, 6, 8, 19) .
Cell culture experiments
MLE-12 mouse lung epithelial cells (ATCC, # CRL-2210) and MH-S mouse alveolar macrophages (ATCC, # CRL-2019) were incubated with 20 mg/mL and 500 ng/mL (MLE-12), or 2 mg/mL and 31.25 ng/mL (MH-S) Jo2/isotype antibody for 30 min, 1, 2, 4, 6, 8, 12, 18, or 24 h for experiments without inhibitors. For experiments with inhibitors, before Jo2/isotype incubation for 6 or 12 h, parthenolide (100 mmol, 1 h before) (Calbiochem, # 512732), SB 203580 (200 mmol, 30 min before) (Promega, # V1161), or PD 98059 (300 mmol, 30 min before) (Promega, # V1191) were added for inhibition of NF-kB, p38MAPK, or ERK1/2, respectively. Cell proliferation was measured as previously described (6) . MCP-1 levels were measured in supernatants by ELISA as described elsewhere (14) . Evidence of apoptosis was assessed by determining the degree of change in activated caspase-3 chemiluminescence levels with a commercially available luminescent assay kit (Caspase-Glo 3/7 Assay, Promega, # G8091) as previously described (7) . In short, addition of the provided reagent to samples results in cell lysis with consecutive release of caspases and subsequent cleavage of the caspase-specific peptide sequence from the substrate within the reagent. In turn, a ''glow-type'' luminescent signal is produced by luciferase and the luminescence is then measured in proportion to the amount of caspase activity present. Background fluorescence (cell culture medium) and a negative reaction (untreated cells) were measured to identify basal caspase activity. Caspase-3 activity was assessed after 15, 30, 45, 60, 75, and 120 min.
Statistical analysis
Data are presented as means AE SEM. Normal distribution was verified by the Kolmogorov-Smirnov test. Statistical analysis included one-or two-factorial analysis of variance (one-way ANOVA, two-way ANOVA) or ANOVA-OnRanks (Kruskal-Wallis test) followed by a Student-Newman-Keuls (SNK) or Bonferroni post hoc test. P <0.05 was considered statistically significant.
RESULTS
Anti-Gr1 treatment reduced circulating PMNs and Fas-induced migration of activated PMNs to the lung
Pulmonary activation of Fas led to a significantly increased amount of neutrophils in blood at 18 h (Fig. 1A) and in BALF at 6 and 18 h (Fig. 1B) . Lung myeloperoxidase (MPO) activity was significantly elevated at 6 and 18 h (Fig. 1C) . We did not observe a Fas-induced increase of PMNs at 18 h in blood or at 6 and 18 h in BALF of PMN-reduced mice (PMN-/FAS) ( Fig. 1 , A and B). Fas-induced MPO activity was also blunted at 18 h by PMN reduction (Fig. 1C ).
Pulmonary Fas activation increased BALF cytokines/ chemokines in the presence but not in the absence of PMN Pulmonary Fas activation markedly increased BALF concentrations of IL-6, IL-10, MCP-1, and G-CSF at 18 h in the presence of neutrophils (Fig. 2 , A-D). For MCP-1, this pattern was also observed at 6 h (Fig. 2B ). In the absence of PMNs, pulmonary Fas activation did not enhance lung mediator concentrations (Fig. 2 , A-E) and even blunted them in the case of G-CSF (Fig. 2D ), MIP-2 (data not shown), and KC ( Fig. 2E) , suggesting neutrophils are an essential prerequisite for Fasinduced upregulation of G-CSF, MIP-2, and KC in BALF at 18 h.
Pulmonary Fas activation increased lung tissue cytokines/chemokines in the presence but not in the absence of PMN Fas activation in the lungs markedly enhanced IL-6, G-CSF, MCP-1, and KC in lung homogenate at 18 h in the presence of neutrophils (Fig. 3 , A-D). For KC, this was also observed at 6 h after Fas activation with a significant increase at 18 h when compared with the 6 h time point (Fig. 3D ). In contrast, in the absence of PMN, activation of Fas did not increase cytokine/mediator release into the lung tissue, with mediator levels already increased in Gr-1-treated animals without Fas activation when compared with their isotype-treated controls. Interestingly, at 6 and 18 h after Fas activation, lung KC concentrations were even decreased in PMN-reduced animals, indicating a crucial role of neutrophils in the regulation of Fasmediated KC production (Fig. 3D ).
Pulmonary Fas activation increased plasma cytokines/ chemokines in the presence but not in the absence of PMN with the exception of KC at 6 h and MCP-1 at 18 h
In the presence of PMN, plasma levels of MCP-1 and KC were significantly increased by pulmonary Fas instillation at 6 and 18 h (Fig. 4, B and D) . IL-6 was increased 18 h after Fas activation (Fig. 4A ). In the absence of PMN, plasma KC was elevated by pulmonary Fas activation at 6, but not at 18 h (Fig. 4D) , whereas MCP-1 was increased at 18 h only (Fig. 4B) . Interestingly, IL-6 was blunted significantly 18 h after Fas instillation in the absence of PMN (Fig. 4A) . Thus, the presence of PMN appears essential for early (6 h) MCP-1 production, late (18 h) KC production, and for upregulation of IL-6 within plasma in response to pulmonary Fas activation. Plasma levels of IL-1b, MIP-2, and IL-10 were not significantly affected by MCP-1 (B) , G-CSF (C), and KC (D) in plasma from mice treated with intravenous Gr-1 (PMNÀ) or its isotype (PMNþ) 48 h prior to intratracheal application of Jo2 (FAS) or isotype (ISO).
* P < 0.05 vs. corresponding ISO, # P < 0.05 vs. corresponding PMNþ, @ P <0.05 vs. corresponding group at 18 h; n ¼ 6. pulmonary Fas activation in the presence or absence of PMN (data not shown).
Fas-induced apoptosis was independent of the presence of PMN At 6 and 18 h after Fas activation, increased lung apoptosis was observed (Fig. 5) . The extent of lung apoptosis induced in PMN-reduced and in naive animals was similar, indicating that the presence of PMN was not a necessary premise for Fasinduced pulmonary apoptosis. Furthermore, TUNEL staining indicated that there was increased apoptosis 18 h after pulmonary Fas activation (Fig. 6) . No difference was found between naive or Gr-1-treated mice in the amount of TUNEL-positive lung cells they exhibited in response to Fas.
Fas-induced lung injury was mediated by neutrophils
An early increase in BALF protein concentration was observed 6 h after Fas activation. In the absence of PMN, no such increase was seen, suggesting a protective effect of neutrophil reduction (Fig. 7A ). Even at 18 h, a reduction of BALF protein concentration was still evident in PMN-reduced animals in response to Fas activation when compared with control animals (Fig. 7A) .
Lung tissue sections of Fas-treated mice showed inflammatory cell influx, alveolar architecture disruption, and alveolar wall thickening in the presence of neutrophils, indicating lung damage (Fig. 7C) . These changes were attenuated in the absence of neutrophils (Fig. 7E) .
Fas induced apoptosis and chemokine/cytokine production in MLE-12 and MH-S cells With respect to cell viability, MLE-12 and MH-S cells displayed no significant differences in total cell counts in response to 500 ng/mL and 20 mg/mL Jo2 (MLE-12) or 31.25 ng/mL and 2 mg/mL Jo2 (MH-S) over 2, 4, 6, 8, 12, 18 , and 24 h incubation period. However, there was a trend toward declining cell numbers starting after 8 h of incubation (n ¼ 4, data not shown). MLE-12 and MH-S cells were treated with different concentrations of Jo2 for varying periods in order to identify the optimal dose-and temporal response to antibody challenge.
In MH-S cells, Fas-induced apoptosis was evident at a minimum concentration of 31.25 ng/mL after 4 h (Fig. 8A) . Due to declining cell viability (data not shown), a maximum concentration of 2 mg/mL of Jo2 was used as it produced a significant increase in apoptosis after 30 min (Fig. 8B) . At 6 and 12 h, Fas-induced apoptosis in response to either 31.25 ng/mL or 2 mg/mL Jo2 was blunted by inhibition of ERK1/2 ( Fig. 9C-F) and, alternatively, significantly increased by inhibition of p38MAPK (2 mg/mL Jo2, 6 h) (Fig. 9E) . The lowest concentration of Jo2 sufficient to lead to marked inflammatory mediator release after 30 min was 31.25 ng/mL with persistent release at 2 mg/mL after 0.5, 1, and 2 h (MCP-1, Fig. 10, A and  B) .
In MLE-12 cells, Fas-induced apoptosis was observed at a minimum Jo2 concentration of 500 ng/mL after 12 h (Fig. 8C) as well as at 4 and 6 h after incubation with 20 mg/mL Jo2 (Figs. 8D and 9A ). The latter was significantly elevated by inhibition of p38MAPK, an observation we also made at 500 ng/mL (data not shown). Inhibition of NF-kB did not influence caspase-3 activity (Fig. 9, A and B) . In MLE-12 cells, inflammatory cytokine release was induced with 500 ng/mL Jo2 in as little as 2 h of incubation and was not further increased by the higher Jo2 concentrations (MCP1, Fig. 10, C and D) .
DISCUSSION
The aim of this study was to investigate the contribution of neutrophils in regulating Fas-induced pulmonary inflammation, apoptosis, and lung damage as well as the role of Fas-activated inflammation and apoptotic pathways in different resident lung cell types/cell lines. Since activation of Fas in the lung induces pulmonary inflammation and apoptosis with subsequent recruitment of activated neutrophils, it is difficult to distinguish these events with respect to their final impact on lung damage. In this regard, intratracheal Jo2 deposition is not to present an animal model of clinical ALI/ARDS, but is rather intended to allow initial mechanistic dissection in the role of local pulmonary Fas activation in this process, as a shared hallmark of a syndrome, caused by distinct patho-genetic events. Here, we have found that the recruitment of neutrophils is mandatory for Fas-induced lung injury to fully develop. Interestingly, Fas-induced lung inflammation but not apoptosis was itself tightly regulated by the presence of neutrophils. This indicates an additional feedback mechanism by these cells, a concept supported by the finding that direct interaction of endothelial cells and neutrophils contributes substantially to inflammatory lung injury (20) . Furthermore, we observed that lung epithelial cells and macrophages respond differently to Fas activation. At a low level of Fas activation AM responded with apoptosis, while LEC appeared to be more resistant, but rather produced PMN attracting chemokines. In this regard, our data indicates that when ALI develops, AM respond first to Fas activation with the release of MCP-1, as this is observed as early as 30 min and, subsequently, undergo apoptosis-mediated by altered NF-kB and ERK1/2-signalling-as this is observed only after 2 to 12 h. With increasing Fas activation, LEC then undergo apoptosis, potentially by an ERK1/2-dependent mechanism and suppression of p38MAPK. Taken together with our in vivo findings that neutrophils also play a role in this process, this may culminate in alveolar-capillary barrier disruption.
Fas-induced pulmonary and systemic inflammation in the presence and absence of PMN
In the presence of PMN, a significant increase in BALF (MCP-1, IL-6, IL-10, G-CSF), lung tissue (MCP-1, KC, IL-6 , G-CSF), and plasma (MCP-1, KC, IL-6) mediators was observed after intratracheal instillation of the Fas agonist Jo2. This data is in line with previous findings indicating a significant release of lung tissue chemokines at 4 h (MCP-1, MIP-2, KC) (6), at 6 h (MCP-1, MIP-2, MIP-1a, IL-6) (12), and at 16 h (KC, MIP-2, TNF-a, IL-1b, IL-6) after in vivo Fas activation (19) . Our observation that pulmonary activation of Fas induced a significant elevation in mediator plasma levels corresponding to the local profile, may be interpreted as a consequence of alveolar-capillary barrier disruption, allowing for a spill-over of locally released pulmonary mediators into the blood.
Interestingly, in the absence of neutrophils, we also observed a markedly increased inflammatory response to Fas (PMNþ vs. PMNÀ) in BALF, lung tissue, and plasma. MCP-1, a key chemokine and an early mediator in ALI, appears to be elevated independently of the type of insult; including in vivo FasL (12), isolated blunt chest trauma (14) , or a double-hit such as chest trauma-induced septic acute lung injury (5) in the presence or the absence of neutrophils in lung tissue. However, here in the setting of in vivo Fas stimulation, pulmonary MCP-1 release was additionally elevated in the absence of neutrophils (PMNþ vs. PMNÀ). These findings suggest that PMN possess antiinflammatory properties that can contribute to containing the local and/or systemic inflammatory response to local lung Fas activation.
Interestingly, in contrast to MCP-1, reduction of PMN blunted the in vivo Fas-induced inflammatory response in the case of KC and IL-6 in lung tissue. This effect was also observed by Lomas-Neira et al. (21) in response to neutrophil reduction in a mouse model of indirect ALI resulting from hemorrhagic shock and septic challenge. Since KC is primarily released by PMN and endothelial cells (22, 23) , the latter of which were shown to be susceptible to Fas-induced apoptosis (19) , the decrease in lung tissue levels of KC after neutrophil reduction and Fas activation may be explicable. PMN also represent a major source of IL-1b in the lung (24) , while pneumocytes release IL-6 after stimulation with IL-1b (25) . Thus, the decrease in IL-6 may be considered a consequence of neutrophil reduction. Interestingly, after AM depletion and consecutive pulmonary Fas activation, lung tissue KC and IL-6 remained unaffected (26) , suggesting modulation by PMN but not AM.
Highlighting the anti-inflammatory capacity of PMN, the potentiation of the in vivo Fas-induced inflammatory response in BALF, lung tissue, and plasma seen here in response to Gr-1 treatment is in accordance with other studies (14, 27) . The reduction of Ly-6C and Ly-6G positive cells might have contributed here. In addition, a residual neutrophil activity of about 10% was observed following Gr-1 treatment, which has been reported in other studies (21, 27) . Finally, from a clinicaltherapeutic point of view, total elimination of PMN after trauma and/or sepsis appears not recommendable anyway.
Fas-induced pulmonary apoptosis in the presence and absence of PMN We observed a significant increase in activated caspase-3 and TUNEL-positive cells at 18 h in response to in vivo pulmonary Fas activation in the presence of neutrophils, confirming the results of other groups at similar time points (12, 19, 26) . We did not observe a significant alteration in apoptosis comparing Gr-1-treated (PMNÀ) and isotype-treated (PMNþ) mice in response to Fas at 6 or 18 h. In line with this observation, wildtype mice and mutant mice lacking Fas on their myeloid cells (e.g., AM, PMN), but not mutant mice expressing Fas in myeloid cells only (and not in LEC), displayed significantly increased pulmonary apoptosis 24 h after intratracheal instillation of Jo2 (28) . In contrast, increased in vivo Fas-induced apoptosis was observed after depletion of resident AM (26) , which might be explained by deficient phagocytosis and degradation of apoptotic PMN by AM (29) . Taken together, a dominant role of epithelial cell apoptosis is suggested, independent of the presence of neutrophils.
Fas-induced lung damage in the presence and absence of PMN With respect to lung damage, we observed an early significant increase in BAL protein concentration after pulmonary Fas activation at 6 h in the presence of PMN. This finding was supported by microscopic evaluation of lung tissue sections (H&E), displaying inflammatory cell influx, alveolar architecture disruption, and alveolar wall thickening in the Fas-treated animals and is in concordance with Matute-Bello et al. (12) . Strikingly, the Fas-induced increase in BAL protein concentration was significantly reduced in the absence of neutrophils. Lung histology sections confirmed the finding of a reduction of lung damage in the absence of activated PMNs. The protective capacity of neutrophil reduction has already been shown in different settings and lead to the distinction of neutrophil dependent-(reperfusion-, immune complex-, sepsis-, or LPS-induced) (24, 30) and neutrophil independent (oleic acid-, hyperoxia-induced) (4) forms of ALI. Fas-induced lung injury requires Fas-expression on non-myeloid cells of the lung (28) and is worsened in the absence of AM (26) . Conversely, activated PMN with the capacity to release cytokines, proteases, elastases, nitric oxide species, reactive oxygen species, myeloperoxidase, and sFasL (30, 31) are suggested as a requirement for Fas-induced lung injury in our study.
Fas-induced inflammation and apoptosis in LEC and AM in vitro
The minimal necessary concentration of Fas activating antibody (Jo2) for apoptosis and inflammatory mediator release was Â16 lower for AM (31.25 ng/mL), when compared with LEC (500 ng/mL). With respect to kinetics, AM displayed an earlier significant release of MCP-1 (30 min) and apoptosis (2 h) when compared with LEC (2 and 4 h, respectively). This suggests an initial response of AM with MCP-1 release and apoptosis due to increasing Fas activation in patients progressing to ALI/ARDS and is in line with other in vitro studies (32) (33) (34) . Interestingly, we found inhibition of p38a-and p38b-MAPK to be of pro-apoptotic potential in MH-S and MLE-12 cells, whereas inhibition of ERK1/2 displayed anti-apoptotic effects. Inhibition of NF-kB blunted Fas-induced apoptosis in AM, but did not show any pro-or anti-apoptotic effects in LEC. The observed anti-apoptotic capacity of p38MAPK has been reported previously and is proposed to mediate the anti-apoptotic effect of CO during ischemia-reperfusion-induced lung injury in vivo (35) . Taken together, signalling via p38a-and p38b-MAPK displayed anti-apoptotic, ERK1/2-signalling proapoptotic potential in LEC and AM. Signalling via NF-kB showed pro-apoptotic capacity in AM but not in LEC.
In conclusion, we found Fas/FasL ligation to be an effective trigger of pulmonary inflammation, apoptosis, and lung damage. Following in vivo activation of the Fas-LEC apoptotic pathway, PMN restrained aspects of lung inflammation with the exception of KC and IL-6 in lung tissue, but also clearly facilitated structural organ damage. In addition, in vivo Fasinduced apoptosis was independent of the presence of PMN, while pulmonary inflammation and lung damage were both modulated by the presence of neutrophils, suggesting Fasinduced lung injury to be explicable by the neutrophil hypothesis of ALI/ARDS (13) . Activation of ERK1/2 was associated with apoptosis in LEC and AM in vitro, whereas p38MAPK presented anti-apoptotic potential. Taken together, secondary lung damage via recruitment of activated PMN into the lungs in response to Fas-mediated inflammation is an important mechanism in the development of structural lung damage and needs to be differentiated from the direct effects of Fas-induced apoptosis. The inhibition of Fas blunts two necessary events in the pathogenesis of ALI, supporting its value as a potential therapeutic target.
